Sorafenib Versus Oral Fluoropyrimidines in The Management of Advanced Hepatocellular Carcinoma
Omar Mohammed Abdelrahman;
Abstract
-156-
SUMMARY
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality, with an estimated worldwide prevalence of 632,000 cases. Accounting for about 90% of all primary liver cancers, H
SUMMARY
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality, with an estimated worldwide prevalence of 632,000 cases. Accounting for about 90% of all primary liver cancers, H
Other data
| Title | Sorafenib Versus Oral Fluoropyrimidines in The Management of Advanced Hepatocellular Carcinoma | Other Titles | مقارنة عقار السورافينيب بأقراص الفلوروبيريميدين في مرضى سرطان الكبد المتقدم | Authors | Omar Mohammed Abdelrahman | Keywords | Sorafenib Versus Oral Fluoropyrimidines in The Management of Advanced Hepatocellular Carcinoma | Issue Date | 2013 | Description | -156- SUMMARY Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality, with an estimated worldwide prevalence of 632,000 cases. Accounting for about 90% of all primary liver cancers, H |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| 115055A5246.pdf | 287.04 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.